RV3 Rotavirus Vaccine: Developing A Neonatal Rotavirus Vaccine Formulation For The Global Community
Funder
National Health and Medical Research Council
Funding Amount
$135,075.00
Summary
Rotavirus infection is the leading cause of severe dehydrating gastroenteritis responsible for approximately 600,000 deaths per year in children under 5 years of age worldwide. There is a commercial and public health opportunity to develop a new rotavirus vaccine that can be given at birth. By modifying the way the vaccine is made we hope that it will be more acceptable and easily delivered to children in remote communities and developing countries without the need for refrigeration.
RV3 Rotavirus Vaccine: Phase I And II Clinical Trials Of A Human Neonatal Rotavirus Vaccine For The Global Community
Funder
National Health and Medical Research Council
Funding Amount
$1,099,123.00
Summary
Rotavirus infection is the leading cause of gastroenteritis responsible for over 600,000 deaths each year in children less than 5 years. Although 2 commercial vaccines are now available in Australia, the high cost and concern about the risk of side effects are barriers to widespread vaccine introduction. The goal of this study is to develop an effective rotavirus vaccine, administered to newborns that is affordable for the global community, able to be introduced cheaply in developing countries w ....Rotavirus infection is the leading cause of gastroenteritis responsible for over 600,000 deaths each year in children less than 5 years. Although 2 commercial vaccines are now available in Australia, the high cost and concern about the risk of side effects are barriers to widespread vaccine introduction. The goal of this study is to develop an effective rotavirus vaccine, administered to newborns that is affordable for the global community, able to be introduced cheaply in developing countries where the burden of morbidity and mortality is greatest.Read moreRead less
Bacterial Inhibition Of Cell Signalling And Apoptosis During Gastrintestinal Infection
Funder
National Health and Medical Research Council
Funding Amount
$542,011.00
Summary
E. coli are a major cause of severe diarrhoeal disease. In order to establish infection, E. coli inhibits a host response where cells with bacteria stuck to them are ‘killed off’ and excreted as waste. This recent discovery illuminated an unknown role for cell death in the immune response during bacterial gastroenteritis. This project will study this phenomenon further to better understand the host immune response to infection and also other gut diseases such as inflammatory bowel disease.
Randomised Controlled Trial Of The Use Of Nitazoxanide Versus Placebo To Treat Gastroenteritis Among Aboriginal Children
Funder
National Health and Medical Research Council
Funding Amount
$1,324,808.00
Summary
Better treatment strategies are needed for Indigenous children with gastroenteritis. At present, most treatment is supportive only, with little effect on the duration of symptoms. Nitazoxanide appears to have effects on a broad range of pathogens which cause gastroenteritis, but it is not clear whether it will be of benefit in this population. We will compare the speed of symptom resolution in children who receive nitazoxanide with a group who receive a placebo instead.